The ABCB10 Knockout SK-OV-3 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population derived from the SK-OV-3 human ovarian adenocarcinoma cell line, carrying a targeted disruption of the ABCB10 gene. This loss-of-function model enables investigation of ABCB10-dependent processes without imposing a single clonal genotype, preserving the heterogeneity of the engineered cell pool for population-level analyses.
SK-OV-3 is a well-established epithelial line originally isolated from the ascitic fluid of a patient with ovarian adenocarcinoma. These cells are widely employed as an ovarian cancer model due to their tumorigenic properties, resistance to certain chemotherapeutics, and representation of high-grade serous carcinoma features. The SK-OV-3 background thus provides a clinically relevant platform for studying mitochondrial biology and drug responses in ovarian cancer.
ABCB10 encodes a mitochondrial inner membrane ATP-binding cassette transporter that is critical for heme biosynthesis and redox homeostasis. ABCB10 interacts with mitoferrin-1 (MFRN1) and ferrochelatase (FECH) to facilitate mitochondrial iron import and heme production. Its expression is regulated by the transcription factors GATA1, STAT3, and TP53. Downstream, ABCB10 influences heme levels, mitochondrial iron content, reactive oxygen species (ROS) accumulation, and the release of cytochrome c, which can activate caspases to initiate the intrinsic apoptosis pathway. The broader pathway includes aminolevulinic acid synthase (ALAS), MFRN1, FECH, heme oxygenase-1 (HO-1), and cytochrome c.
In the SK-OV-3 ovarian cancer context, ABCB10 disruption impairs mitochondrial heme synthesis, leading to iron dysregulation and heightened oxidative stress. This metabolic vulnerability compromises cell survival and may sensitize cells to apoptosis, underscoring ABCB10’s role in maintaining mitochondrial integrity. The model is therefore pertinent for dissecting how mitochondrial transporters support tumor cell adaptation and for identifying targetable dependencies in ovarian cancer.
Researchers can employ this polyclonal knockout population to dissect ABCB10 function through western blotting of heme-related proteins, RT-qPCR, mitochondrial ROS measurements, apoptosis and viability assays, and heme quantification. Co-immunoprecipitation studies with MFRN1 and drug sensitivity screening using mitochondrial toxins further broaden utility. These cells support mechanistic investigations of heme metabolism, oxidative stress signaling, and ovarian cancer cell survival. For additional details, please contact Ascent Research.
